# Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer

> **NCT05564286** · PHASE3 · COMPLETED · sponsor: **Shantou University Medical College** · enrollment: 116 (actual)

## Conditions studied

- Cervical Cancer
- Nasopharyngeal Cancer
- Chemotherapy-induced Nausea and Vomiting
- Radiation-Induced Nausea and Vomiting
- Antiemetic

## Interventions

- **DRUG:** Fosaprepitant
- **DRUG:** tropisetron
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05564286
- **Lead sponsor:** Shantou University Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-01
- **Primary completion:** 2023-07-31
- **Final completion:** 2023-08-30
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2024-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05564286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05564286, "Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05564286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*